2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4402 Patient preferences for chronic lymphocytic leukemia treatment attributes in Canada: A discrete choice experiment

Versha Banerji, MD, Ghislain Cournoyer, MD2, Paola Maria Christina Lembo, PhD3, Mei Xue4, Todor Totev, MBA5, Chris Lenhu6, Yan Meng, PhD7, Zhuo Chen8, Fengyi Jiang9, Dominic Pilon, MA10, Pauline Sage, PharmD, RPh11, Keri Yang12, Sarit E. Assouline, MDCM, MSc, FRCPC13
1 University of Manitoba and the Paul Albrectsen Research Institute, CancerCare Manitoba, Winnepeg, Manitoba, Canada
2 Hôpital de Saint-Jérôme, CISSS des Laurentides, Saint-Jérôme, Quebec, Canada
3 BeOne Medicines (Canada) ULC, Toronto, Ontario, Canada
4 BeOne Medicines Ltd, San Carlos, California, United States
5 Analysis Group, Inc., Boston, Massachusetts, United States
6 BeOne Medicines (Canada) ULC, Toronto, Ontario, Canada
7 Analysis Group, Inc., Boston, Massachusetts, United States
8 Analysis Group, Inc., Boston, Massachusetts, United States
9 Analysis Group, Inc., Toronto, Ontario, Canada
10 Analysis Group, Inc., Montreal, Quebec, Canada
11 BeOne Medicines (Canada) ULC, Toronto, Ontario, Canada
12 BeOne Medicines Ltd, San Carlos, California, United States
13 Jewish General Hospital, McGill University, Montreal, Quebec, Canada

Introduction: Treatments for chronic lymphocytic leukemia (CLL) differ in efficacy, safety, treatment duration, and monitoring needs; all of which can affect patients’ treatment experience and outcomes. Although targeted therapies, including Bruton tyrosine kinase inhibitors (BTKis), have transformed CLL management, limited evidence is available on how patients with CLL in Canada value treatment attributes. To better understand patient preferences regarding CLL treatment attributes, a quantitative analysis using a discrete choice experiment (DCE) was conducted.

Methods: A patient survey with a DCE design was administered online from May 4 to June 1, 2026, among Canadian adults aged ≥18 years diagnosed with CLL. Patients were recruited through a patient support group. Treatment attributes were selected based on a targeted literature review and clinical input. Patients completed 11 DCE choice tasks, including a dominance test, evaluating attributes related to efficacy, safety, and treatment convenience. Efficacy was represented by progression-free survival (PFS) of 3, 5, or 7 years; safety by the absence of, mild, moderate, or significant impacts on quality of life (QoL) of diarrhea, headache, atrial fibrillation, hypertension, and kidney dysfunction; and convenience by treatment duration and monitoring/hospitalization requirements. A conditional logistic regression model was used to estimate preference weights and calculate the relative importance of each attribute and willingness-to-trade-off.

Results: A total of 64 patients completed the survey (mean age: 69 years; 97% White; 48% female; 67% with a Bachelor’s degree or above; 52% from Ontario with others from Prairies, Atlantic, British Columbia, and Quebec; 73% retired; 86% with provincial reimbursement; 92% had prescription drug insurance). Slightly less than half (48%) were diagnosed ≥5 years ago. In terms of treatment experience, 39% of patients were treatment-naïve, while 61% were treatment-experienced (39% first-line, 19% second-line, 3% third-line or later). Among treatment-experienced patients, the most reported prior treatment-related side effects were fatigue or extreme tiredness (67%), diarrhea (44%), nausea and/or vomiting (39%), and neutropenia (31%). Longer PFS and lower QoL impact from each evaluated side effect were significant predictors of treatment choice (P<.001), whereas treatment convenience had minimal influence on treatment preferences. The attributes ranked from most to least important were the impacts of diarrhea (18.6%), headache (18.1%), atrial fibrillation (17.8%), kidney dysfunction (16.3%), and hypertension (15.0%) on QoL, followed by PFS (13.8%) and treatment convenience (0.4%). The five side-effect-related QoL attributes were similar in relative importance and each ranked above PFS and treatment convenience. Willingness-to-trade-off analyses further indicated that patients were willing to accept shorter PFS to avoid significant QoL impacts from the evaluated treatment-related side effects.

Conclusions: Canadian patients with CLL prioritized minimizing the impact of treatment-related side effects on QoL over all other treatment attributes, with PFS ranking second in importance. Treatment convenience was comparatively less influential. These findings underscore the critical role of QoL considerations alongside efficacy in treatment selection and support the integration of patient preferences into shared decision-making to optimize patient-centered care.

Versha Banerji, MD: The University of Manitoba - Research Funding; Canadian Institutes of Health Research - Research Funding; BeOne - Research Funding; CancerCare Manitoba Foundation - Research Funding; Janssen - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Lilly Oncology Canada - Research Funding; Biogen - Patents & Royalties; Merck - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Lilly Oncology Canada - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); CancerCare Manitoba Foundation - Current Employment; The University of Manitoba - Current Employment